Management of chronic hepatitis C in 2008;Prise en charge de l'hépatite C en 2008

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 3 PART 2, 2008, Pages

  Pol, S ^a   Marcellin, P ^b  

^a Hôpital Cochin ^*  (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Cirrhosis; Fibrosis; Hepatitis C

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; PEGINTERFERON; RIBAVIRIN; STAVUDINE; ZIDOVUDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; NONHUMAN; TREATMENT RESPONSE;

EID: 50849097295     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(08)73275-5     Document Type: Article

References (34)

1. Pessione F., Degos F., Marcellin P., Duchatelle V., Njapoum C., Martinot-Peignoux M., et al. Effect of alcohol consumption on serum HCV RNA and histological lesions in chronic hepatitis C. Hepatology 27 (1998) 1717-1722
2. Everhart J.E. Alcohol and Hepatitis C: do we have a drinking problem. Gastroenterology 130 (2006) 1912-1919
3. Hutchinson S.J., Bird S.M., and Goldberg D.J. Influence of alcohol on the progression of hepatitis C virus infection: a meta analysis. Clin Gastroenterol Hepatol 3 (2005) 1150-1159
4. Serfaty L., Mathurin P., Cadranel J.F., and Tran A. Alcool, syndrome métabolique et obésité : impact sur la réponse ou traitement. Gastroenterol Clin Biol 31 (2007) 4S40-4S43
5. Patton H.M., Patel K., and Mc Hutchinson J.G. Hepatitic steatosis in chronic hepatitis C virus infection: a review of mechanisms, influence or natural history and treatment outcomes. Hepatology Rev 1 (2004) 72-80
6. Younossi Z.M., Mc Cullough A.J., Ong J.P., Barnes D.S., Post A., Tavili A., et al. Obesity and non alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 38 (2004) 705-709
7. Alberti K.G.M.M., Zimmet P., and Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 366 (2005) 1059-1061
8. Asselah T., Rubbia-Brandt L., Marcellin P., and Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut 55 (2006) 122-130
9. Bedossa P., Moucari R., Chelbi E., Asselah T., Paradis V., Vidaud M., et al. Evidence for a role of non alcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 46 (2007) 380-387
10. Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.P., et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134 (2008) 416-423
11. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernandez-Rodriguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
12. Pol S., Cacoub P., Pialoux G., Benhamou G., Halfon P., Rosenthal E., et al. Prise en charge des patients co-infectés VIH-VHC. Gastroenterol Clin Biol 31 (2007) 4S7-4S12
13. Moussalli J., Melin P., Wartelle C., and Lang J.P. Prise en charge de l'hépatite C chez les patients utilisateurs de drogues. Gastroenterol Clin Biol 31 (2007) 4S51-4S55
14. Cacoub P., Halfon P., Rosenthal E., Pialoux G., Benhamou Y., Perronne C., et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life". Modifications in two large surveys between 2004 and 2006. J Hepatol 48 (2008) 35-42
15. Alberti A., Ciumeck N., Coolins S., Gerlich W., Lundgren J., Palu G., et al. Short statement on the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 (2005) 615-624
16. Marcellin P., Heathcote E.J., and Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the "accordion" regimen ?. J Hepatol 47 (2007) 580-587
17. Zarski J.P., Bedossa P., Bronowicki J.P., Doffoel M., and Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l'hépatite C en 2007. Gastroenterol Clin Biol 31 (2007) 4S34-4S39
18. Marrache F., Consigny Y., Ripault M.P., Cazals-Hatem D., Martinot M., Boyer N., et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 12 (2005) 421-428
19. Trinchet J.C., and Groupe GRETCH. Screening for hepatocellular carcinoma (HCC) in patients with cirrhosis. A multicenter randomized trial comparing two periodicities of ultrasonographic (US) screening, 3 months vs 6 months (abstract). J Hepatol 45 (2007) S56
20. Ganne-Carrié N., Chastang C., Chapel F., Munz C., Paterson D., Sibony G., et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology 23 (1996) 1112-1118
21. Marrero J.A., Fontana R.J., Fu S., Conjeevaram H.S., Lu G.L., and Lok A.S. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42 (2005) 218-224
22. Hassan M.M., Hwang L.Y., Hatter C.J., Swaim M., Li D., Abbruzzese J.L., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36 (2002) 1206-1213
23. Bruix J., Sherman M., Practice Guidelines Committee, and American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
24. Caturelli E., Solmi L., Anti M., Fusilli S., Roselli P., Andriulli A., et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis : a multicentre study. Gut 53 (2004) 1356-1362
25. Pol S., and Bourlière M. Optimizing treatment outcomes in chronic hepatitis C: management of non response. Antiviral Therapy 11 (2006) 955-970
26. Marcellin P., Bourlière M., Pawlotsky J.M., and Ouzan D. Malades atteints d'hépatite chronique C non répondeurs : définitions de la non réponse et stratégies thérapeutiques. Gastroentérol Clin Biol 31 (2007) 4S13-4S19
27. Trépo C., Marion-Audibert A.M., Samuel D., Guyader D., and Fontanges T. Traitement d'entretien. Gastroenterol Clin Biol 31 (2007) 4S29-4S33
28. Moucari R., Ripault M.P., Oulès V., Martinot-Peignoux M., Asselah T., Boyer N., et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirine of chronic hepatitis C patients non responders to standard combination therapy. J Hepatol 46 (2007) 596-604
29. Larrey D., Couzigou P., and Denis J. Hépatite chronique C : gestion des effets indésirables du traitement. Gastroenterol Clin Biol 31 (2007) 4S20-4S28
30. Shiffman M.L., Ghany M.G., Morgan T.R., Wright E.C., Everson G.T., Lindsay K., et al. Impact of reducing peginterferon α-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132 (2007) 103-112
31. Castera L., Constant A., Henry C., Champbenoit P., Bernard P.H., de Lédinghen V., et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 24 (2006) 1223-1230
32. Marcellin P. L'hépatite en 2007 « des progrès. Peut-on mieux faire ... ». Gastroenterol Clin Biol 31 (2007) 4S3-4S6
33. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-α-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
34. Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694